This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Semaglutide and alcohol consumption

Authoring team

Growing evidence indicates that the glucagon-like peptide-1 (GLP-1) system is involved in the neurobiology of addictive behaviours, and GLP-1 analogues may be used for the treatment of alcohol use disorder (AUD) (1):

  • in animal models, the GLP-1 analogue semaglutide decreased alcohol intake across different drinking models and species and modulated central GABA neurotransmission

In a retrospective cohort study of electronic health records of 83,825 patients with obesity (2):

  • was shown that semaglutide (compared with other anti-obesity medications) was associated with a 50%-56% lower risk for both the incidence and recurrence of alcohol use disorder for a 12-month follow-up period
  • consistent reductions were seen for patients stratified by gender, age group, race and in patients with and without type 2 diabetes
  • similar findings were replicated in the study population with 598,803 patients with type 2 diabetes

Reference:

  1. Chuong V et al. The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight. 2023 Jun 22;8(12):e170671.
  2. Wang, W., Volkow, N.D., Berger, N.A. et al. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nat Commun15, 4548 (2024)

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.